Successful Dasatinib Treatment of Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma and BCR-ABL1-Positive Chronic Myeloid Leukemia: A Case Report

Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI), inhibits multiple kinase pathways and is a promising anti-tumor agent for various solid tumors, including lung cancer. Herein, we report a patient with coexisting epidermal growth factor receptor (EGFR)-mutant lung adenocarcino...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsukaguchi, Akihiro, Minami, Seigo, Yasuoka, Hironao, Kin, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808130/
https://www.ncbi.nlm.nih.gov/pubmed/36605226
http://dx.doi.org/10.1159/000527767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808130/
https://www.ncbi.nlm.nih.gov/pubmed/36605226
http://dx.doi.org/10.1159/000527767

Ejemplares similares